A research team led by scientists at Virginia Commonwealth University reports that a protein called GRP78 could be a universal therapeutic target for treating human diseases such as brain cancer, Ebola, Influenza, hepatitis, and superbug bacteria such as MRSE and MRSA.
The preclinical study, “GRP78/BiP/HSPA5/Dna K is a universal
therapeutic target for human disease”, is published in the Journal of
By using a drug combination of the clinically tested OSU-03012 (AR-12)
and FDA-approved Phosphodiesterase 5 Inhibitors (Viagra, Cialis) to
target GRP78 and related proteins, researchers prevented the replication
of a variety of major viruses in infected cells, made
antibiotic-resistant bacteria vulnerable to common antibiotics and found
evidence that brain cancer stem cells were killed. Data were obtained
in multiple brain cancer stem cell types, and using Influenza, Mumps,
Measles, Rubella, RSV, CMV, Adenovirus, Coxsakie virus, Chikungunya,
Ebola, Hepatitis, E. coli, MRSA, MRSE, and N. gonorrhoeae, among others.
“Basically, we’ve got a concept that by attacking GRP78 and related
proteins: (a) we hurt cancer cells; (b) we inhibit the ability of
viruses to infect and to reproduce; and (c) we are able to kill superbug
antibiotic-resistant bacteria,” said Paul Dent, Ph.D., professor in
the department of biochemistry and molecular biology at VCU School of
Medicine, and universal chair for signal transduction.